Rhythm Pharmaceuticals (RYTM) Return on Sales (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.01%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.01%, up 1.0% from the prior year.
• Return on Sales fell to 0.01% in Q1 2026 per RYTM's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Sales peaked at 0.05% in Q4 2022 and troughed at 0.35% in Q1 2022.
• A 5-year average of 0.04% and a median of 0.02% in 2025 frame the typical range for Return on Sales.
• On a YoY basis, Return on Sales climbed as much as 124 bps in 2022 and fell as far as 1285 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 0.05% in 2022, then tumbled by 133 bps to 0.02% in 2023, then surged by 40 bps to 0.01% in 2024, then grew by 20 bps to 0.01% in 2025, then dropped by 12 bps to 0.01% in 2026.
• Business Quant data shows RYTM's Return on Sales at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.